Halozyme views its drug delivery technology for biologic medicines as complementary to Evotec’s biologic drug manufacturing capabilities. But according to Halozyme, Evotec was unwilling to engage in any merger discussions. The post Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy appeared first on MedCity News.
Seen Health emerged from stealth on Monday. The company builds on the Program of All-Inclusive Care for the Elderly model and focuses on Asian and Pacific Islander communities. The post Twin Brothers Launch Seen Health with $22M to Provide Culturally-Focused Care for Seniors appeared first on MedCity News.
During a recent panel discussion, three healthcare experts discussed reasons why value-based care is struggling to reach scale. The post Value-Based Care Is a Four Layer Cake — Why Do We Only Focus on The Icing? appeared first on MedCity News.
A patient death in a clinical trial usually prompts the FDA to impose a clinical hold. But Neurogene is able to avoid a lengthy clinical trial pause largely because of its participation in an FDA pilot program intended to speed up the development of therapies for rare diseases. The post Patient Dies in Gene Therapy…
By addressing each community’s unique needs with tailored, culturally responsive care and cross-sector collaboration, we can empower healthcare providers to drive lasting, equitable outcomes. The post Closing America’s Diabetes Divide: A $412 Billion Opportunity to Transform Diabetes Care appeared first on MedCity News.
Wearable devices, such as a glucose meter device or a defibrillator and pacemaker, can provide valuable and real-time information to a healthcare provider so that decisions can be made to protect the patient. The post Wearable Health Tech: Innovations and Impacts on Chronic Disease Management appeared first on MedCity News.
President-Elect Donald Trump nominated celebrity physician Dr. Mehmet Oz to lead CMS. Healthcare leaders have mixed feelings on the news — for instance, one CEO pointed out that Dr. Oz could advance the food-as-medicine movement, and others noted that his appointment may decrease pharmaceutical innovation and access to certain medications. The post 5 Healthcare CEOs…
Experts aren’t sure what the outcome of the DOJ’s recent lawsuit against the proposed UnitedHealth Group/Amedisys merger will be under the incoming Trump administration. The Biden administration has focused more on supporting clinicians, while the previous Trump administration favored corporations. Additionally, one expert noted that this case differs from other antitrust lawsuits because it does…
Kura Oncology already had a broad development plan for ziftomenib in leukemias, but the agreement with Kyowa Kirin provides the cash to execute it and a partner to commercialize the drug globally. Ziftomenib is in the same class of medicines as Syndax Pharmaceuticals’ Revuforj, which won FDA approval last week. The post Kura Oncology Gets…
Reducing diagnostic error is a significant part of healthcare organizations’ efforts to improve patient outcomes. By using data to recognize vulnerabilities in the diagnostic process, empowering their diagnostic teams and fostering an environment where every team player understands their vital role organizations can proactively correct the potential root causes of diagnostic errors. The post Strategies…